Evaluation of the effect of Adalimumab in rheumatoid arthritis patients

Evaluation of the effect of Adalimumab on mitochondrial function and Sonic hedgehog signaling pathway in peripheral blood mononuclear cells in rheumatoid arthritis patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211005052683N1

Enrollment

Registered

2021-11-23

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention group: Rheumatoid arthritis patients will receive 40 mg of adalimumab (SinnoRa) by injection every two weeks for 12 weeks. The drug is a product of Sinnagen Company..

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed and voluntary consent Passing the initial treatment period Sero positive patients will be included in the study Preparation for receiving biological medicine with physician approval

Exclusion criteria

Exclusion criteria: All patients with a history of autoimmune, inflammatory, infectious disease in the last 6 months taking biologic anti-TNF drug previous treatment with adalimumab

Design outcomes

Primary

Measure	Time frame
Determining the effect of adalimumab on mitochondrial function. Timepoint: Before and after taking the drug. Method of measurement: Reactive oxygen species and mitochondrial membrane potential are assessed by flow cytometry and Adenosine Triphosphate by luminescence. The sum of these cases indicates mitochondrial function.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnahita Abbasifard

Hamedan University of Medical Sciences

a.abbasifard722@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026